{"id":"NCT02734693","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.","officialTitle":"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-30","primaryCompletion":"2017-02-28","completion":"2017-02-28","firstPosted":"2016-04-12","resultsPosted":"2020-03-27","lastUpdate":"2020-03-27"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention-Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"dasotraline 4mg","otherNames":["SEP-225289"]},{"type":"OTHER","name":"Placebo","otherNames":["Placebo comparitor"]}],"arms":[{"label":"Dasotraline 4mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.","primaryOutcome":{"measure":"Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of the 7 Assessments Collected Across the 12-hour Classroom Day(12 to 24 Hours Postdose)","timeFrame":"Baseline to Day 15","effectByArm":[{"arm":"Placebo","deltaMin":1.99,"sd":0.949},{"arm":"Dasotraline 4mg","deltaMin":-3.19,"sd":0.942}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Affect lability","Insomnia","Decreased appetite","Headache","Irritability"]}}